Literature DB >> 31175989

Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment.

Prachi Shekhawat1, Varsha Pokharkar2.   

Abstract

Quality by design (QbD) principles were implemented to understand the product and process variables of sonoprecipitation technique, for preparation of eprosartan mesylate (EM) nanosuspension. Quality risk management approach was utilized to identify and assess high-risk attributes affecting critical quality attributes (CQA's), prioritizing the number of experiments. The effect of critical material attributes (CMA's) and critical process parameters (CPP's) (soluplus concentration, drug concentration ultrasonication amplitude) on z-average particle size and PDI were investigated using a central composite face-centered design (CCF). Further, design space with criteria set of CMA's and CPP's was established to offer assurance of quality. The optimal formulation, identified using numerical optimization method, was further lyophilized and evaluated for redispersibility, solubility saturation, dissolution kinetic and in-vitro dissolution behavior. The EM nanoparticles were in an amorphous state as confirmed by differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies. The stability study conducted for a span of 6 months attests physical and chemical stability of EM dry nanosuspension in an amorphous state when stored at 4 °C. The enhanced solubility and in-vitro dissolution of EM nanosuspension may be attributed to the reduced particle size and alteration of the physical state from a crystalline to an amorphous state. Further, the optimized formulation was subjected to in-vitro and ex-vivo transport study using parallel artificial membrane permeability assay (PAMPA) and rat everted gut sac model respectively. The transport studies revealed successful permeation enhancement of EM nanoparticle when compared with EM API and physical mixture (PM). The absolute bioavailability of EM API was 7.1% and improved to 39.9% for EM nanosuspension, suggesting that nanoformulation had overcome solubility and permeability limited bioavailability which was observed with EM API.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioavailability; Nanosuspension; PAMPA permeability; Quality by design; Risk assessment

Mesh:

Substances:

Year:  2019        PMID: 31175989     DOI: 10.1016/j.ijpharm.2019.06.006

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.

Authors:  Komal Parmar; Kirti Oza
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

2.  Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology.

Authors:  Abdul Ahad; Yousef A Bin Jardan; Mohd Zaheen Hassan; Mohammad Raish; Ajaz Ahmad; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Solid Self-Nano Emulsifying Nanoplatform Loaded with Tamoxifen and Resveratrol for Treatment of Breast Cancer.

Authors:  Nupur Shrivastava; Ankit Parikh; Rikeshwer Prasad Dewangan; Largee Biswas; Anita Kamra Verma; Saurabh Mittal; Javed Ali; Sanjay Garg; Sanjula Baboota
Journal:  Pharmaceutics       Date:  2022-07-18       Impact factor: 6.525

4.  Development and Evaluation of Docetaxel-Phospholipid Complex Loaded Self-Microemulsifying Drug Delivery System: Optimization and In Vitro/Ex Vivo Studies.

Authors:  Miao Wang; Sung-Kyun You; Hong-Ki Lee; Min-Gu Han; Hyeon-Min Lee; Thi Mai Anh Pham; Young-Guk Na; Cheong-Weon Cho
Journal:  Pharmaceutics       Date:  2020-06-12       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.